Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

Despite economic slowdown, Central and Eastern European countries still represent an attractive healthcare market

Despite the global economic decline, Central and Eastern European (CEE) countries such as Poland, the Czech Republic, Slovakia, Hungary, Bulgaria and Romania still represent an attractive healthcare market.

10 Nov 2009

OriGene Technologies' over-expression lysates adopted for Human Protein Atlas project

OriGene Technologies, Inc. today announced Royal Institute of Technology in Sweden has adopted its VERIFY Tagged Antigen(TM) (Over-expression Lysates) in the Human Protein Atlas program. This program is funded by the Knut and Alice Wallenberg Foundation and is set up to explore the human proteome systematically using Antibody-Based Proteomics.

10 Nov 2009

Compugen discovers new biomarker for predisposition to type 2 diabetes using its GeneVa platform

Compugen Ltd. announced today the discovery and experimental confirmation of a genetic biomarker, CGEN-40001 for predisposition to type 2 diabetes, the most common form of diabetes.

9 Nov 2009

Clinical Data announces financial results for its second fiscal quarter ended September 30, 2009

Clinical Data, Inc. today announced the Company’s operational and financial results for its second fiscal quarter ended September 30, 2009.

9 Nov 2009

Compugen signs research and license agreement with a leading diagnostic company

Compugen Ltd. announced today that it has signed a research and license agreement with a leading diagnostic company covering CGEN-226, a novel biomarker candidate for early detection of preeclampsia.

5 Nov 2009

Exelixis to present 13 abstracts of its development candidates at the 2009 AACR-NCI-EORTC Conference

Exelixis, Inc. announced today that thirteen abstracts related to the company’s development candidates have been accepted for presentation at the 2009 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being held November 15-19 in Boston. Interim data from ongoing phase 1 clinical trials of XL147 and XL765 will be reported in four poster presentations.

4 Nov 2009

Predictive Biosciences commences clinical trials of its bladder cancer assay

Predictive Biosciences Inc. today announced the publication of pilot study results in the November issue of the Journal of Urology, highlighting the Company’s novel urinary biomarker approach to bladder cancer detection that achieves exceptionally high Negative and Positive Predictive Values (NPV and PPV).

4 Nov 2009

Aethlon Medical begins collaborative biomarker program to study neurodegenerative disease

Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) announced today that it has initiated a collaborative biomarker discovery program with the Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine and the Sports Legacy Institute (SLI).

3 Nov 2009

A new blood test for breast cancer

A healthy 44-year-old woman will celebrate many future birthdays thanks to the efforts of Dr. Keri Sweeten and a new blood test for breast cancer

3 Nov 2009

SQI Diagnostics' SQiDworks automated platform and IgXPLEX RA assay receive FDA marketing clearance

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based biomarker testing, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's automated SQiDworks(TM) Diagnostics Platform and its multiplexed IgXPLEX(TM) rheumatoid arthritis (RA) assay for marketing in the United States.

2 Nov 2009

London Genetics enters an intensive partnering programme

London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, has entered an intensive partnering programme following on from its successful pharmacogenetic conference in September.

31 Oct 2009

Quintiles and Eisai partner to develop potential oncology products

Quintiles today announced a strategic alliance with leading global pharmaceutical company Eisai Co., Ltd. (Tokyo, Japan) to develop six potential oncology products in Eisai’s R&D pipeline. Under the terms of the agreement, Quintiles’ oncology experts will conduct Phase II proof-of-concept studies for 11 solid tumor indications. A key goal of the alliance is to determine the efficacy of the products in the shortest possible time in order to bring therapies to market faster for the benefit of cancer patients worldwide.

31 Oct 2009

NIH awards Charles Drew University $9.8M to reduce cancer health disparities in underserved populations

Charles Drew University has been awarded $9.8 million from three major national funders to support the university's long-term, UCLA partnership aimed at reducing the risk of cancer among minorities in poor and disadvantaged communities.

30 Oct 2009

IGR Genomic Center awarded ISO 9001 certification

The Institut de cancérologie Gustave Roussy (IGR) France announced today that its Genomic Center has been awarded ISO 9001 certification for quality management and compliance to the highest standards of quality by Association Française de Normalisation (AFNOR), France’s national organization for standardization and certification.

30 Oct 2009

Studies demonstrate that investigational cancer vaccines show encouraging immune response rates

Results of two phase 1 studies demonstrate that the novel, investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates and objective tumor response in advanced melanoma, prostate cancer and other solid malignancies, setting the stage for phase 2 studies.

30 Oct 2009

NeuroVigil and Roche collaborate to speed up drug development for CNS disorders

Today, leading California Neurotechnology company NeuroVigil and Swiss Pharma giant Roche announced an agreement regarding a major innovation in collecting and analyzing data from clinical trials.

30 Oct 2009

Researchers report preclinical results of a novel PET biomarker designed to detect malignant breast tumors

Researchers at Thomas Jefferson University in Philadelphia, PA, supported in part by NuView Life Sciences, have published an article in the Journal of Nuclear Medicine reporting preclinical results of a novel PET biomarker designed to selectively detect malignant breast tumors.

30 Oct 2009

Positive results from Genta's Phase 3 trial of Genasense

Genta Incorporated today announced top-line results from AGENDA, the Company’s Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. AGENDA is a randomized, double-blind, placebo-controlled trial of dacarbazine administered with or without Genasense® in patients who have not previously received chemotherapy.

29 Oct 2009

Interleukin Genetics and Amway Global sign partnership agreement

Interleukin Genetics, Inc. announced today it has entered into an agreement with Amway Global. With this agreement, Amway Global Independent Business Owners will be able to sell Interleukin Genetics' Inherent Health(TM) brand of genetic tests, including the new Weight Management Genetic Test.

29 Oct 2009

Clinical Data raises $47.4 million through public offering of shares

Clinical Data, Inc. today announced that it has raised gross proceeds of approximately $47.4 million through the public offering of 2,750,000 newly issued shares of its common stock at a price of $17.25 per share. All of the shares are being offered by Clinical Data, Inc.

28 Oct 2009

Biomarker News and Research

Further Reading

Despite economic slowdown, Central and Eastern European countries still represent an attractive healthcare market

OriGene Technologies' over-expression lysates adopted for Human Protein Atlas project

Compugen discovers new biomarker for predisposition to type 2 diabetes using its GeneVa platform

Clinical Data announces financial results for its second fiscal quarter ended September 30, 2009

Compugen signs research and license agreement with a leading diagnostic company

Exelixis to present 13 abstracts of its development candidates at the 2009 AACR-NCI-EORTC Conference

Predictive Biosciences commences clinical trials of its bladder cancer assay

Aethlon Medical begins collaborative biomarker program to study neurodegenerative disease

A new blood test for breast cancer

SQI Diagnostics' SQiDworks automated platform and IgXPLEX RA assay receive FDA marketing clearance

London Genetics enters an intensive partnering programme

Quintiles and Eisai partner to develop potential oncology products

NIH awards Charles Drew University $9.8M to reduce cancer health disparities in underserved populations

IGR Genomic Center awarded ISO 9001 certification

Studies demonstrate that investigational cancer vaccines show encouraging immune response rates

NeuroVigil and Roche collaborate to speed up drug development for CNS disorders

Researchers report preclinical results of a novel PET biomarker designed to detect malignant breast tumors

Positive results from Genta's Phase 3 trial of Genasense

Interleukin Genetics and Amway Global sign partnership agreement

Clinical Data raises $47.4 million through public offering of shares

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News